Comorbidity, not patient age, is associated with impaired safety outcomes in vedolizumab‐ and ustekinumab‐treated patients with inflammatory bowel disease—a prospective multicentre cohort study

BACKGROUND: Few data are available on the effects of age and comorbidity on treatment outcomes of vedolizumab and ustekinumab in inflammatory bowel disease (IBD). AIMS: To evaluate the association between age and comorbidity with safety and effectiveness outcomes of vedolizumab and ustekinumab in IB...

Descripción completa

Detalles Bibliográficos
Autores principales: Asscher, Vera E. R., Biemans, Vince B. C., Pierik, Marieke J., Dijkstra, Gerard, Löwenberg, Mark, van der Marel, Sander, de Boer, Nanne K. H., Bodelier, Alexander G. L., Jansen, Jeroen M., West, Rachel L., Haans, Jeoffrey J. L., van Dop, Willemijn A., Weersma, Rinse K., Hoentjen, Frank, Maljaars, P. W. Jeroen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Efficacy and Safety of Biologics for Crohn's Disease
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7539998/
https://www.ncbi.nlm.nih.gov/pubmed/32901983
http://dx.doi.org/10.1111/apt.16073

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7539998/
https://www.ncbi.nlm.nih.gov/pubmed/32901983
http://dx.doi.org/10.1111/apt.16073

Ejemplares similares